prevalence of low responders to statin therapy

Proportion of low responders to statin therapy and its predictors: A tertiary care hospital based prospective interventional study - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080954

Enrollment

300

Registered

2025-02-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery

Interventions

Intervention1: Tab Rosuvastatin 20 mg: Tab Rosuvastatin 20 mg HS for 4 weeks Control Intervention1: NOT APPLICABLE: NOT APPLICABLE

Sponsors

SHAMLI THAKUR

Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. patients with LDL more than or equal to 100 mg/dl with or without risk factors like smoking, obesity, hypertension, DM 2. Patients with LDL less than 100 mg/dl with risk factors

Exclusion criteria

Exclusion criteria: 1. patients on other lipid lowering medications 2. patients not tolerating rosuvastatin 3. patients with active liver disease and myopathy 4. pregnancy

Design outcomes

Primary

Measure	Time frame
1. To estimate the Prevalence of low responders to Rosuvastatin in patients with atherosclerotic vascular disease and or at intermediate to high riskTimepoint: 4 weeks	—

Secondary

Measure	Time frame
1. To study the clinical determinants of low responders to Rosuvastatin therapyTimepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDr Shamli thakur

INDIRA GANDHI MEDICAL COLLEGE SHIMLA (H.P)

dr.anamika.thakur@gmail.com8894535927

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026